We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Expands Global Research Network for Photon-Counting CT
Read MoreHide Full Article
Key Takeaways
GE HealthCare expands its Photonova Spectra research network across North America, Europe and Asia.
Seven institutions will assess photon-counting CT for cardiac imaging, tissue analysis and low-dose scans.
Photonova Spectra's Deep Silicon technology delivers ultra-high-definition spectral imaging.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced an expansion of its global clinical and research collaborations to advance Photonova Spectra, its next-generation photon-counting CT system. Seven leading healthcare and research institutions across North America, Europe and Asia will evaluate the technology across various clinical applications, imaging protocols and diagnostic settings. The initiative follows Photonova Spectra's CE Mark, FDA 510(k) clearance and regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency, supporting the next phase of its clinical adoption.
Per management, the company's Deep Silicon photon-counting CT technology has the potential to enhance clinicians' ability to visualize and interpret scans, opening new opportunities for early disease detection, personalized treatment and greater diagnostic confidence. GE HealthCare believes close collaboration with leading research institutions will help generate clinical evidence and real-world experience to establish new applications for the technology and support better patient care.
GEHC Stock Trend Following the News
Shares of GEHC have lost 1.4% since the announcement on Monday. Year to date, the stock has inched down 0.7% compared with the industry’s 15.3% fall. However, the S&P 500 has risen 7.2% during the same timeframe.
The expanded research network could strengthen GEHC's competitive position in the advanced medical imaging market and support the commercial potential of Photonova Spectra. Collaborations with prestigious healthcare institutions may help build clinical confidence in the technology, encourage broader adoption and create new demand across specialized imaging applications. The initiative also provides opportunities to refine the product based on real-world clinical feedback, reinforcing GE HealthCare's innovation leadership and supporting its long-term medical imaging growth.
GEHC currently has a market capitalization of $37.51 billion.
Image Source: Zacks Investment Research
More on the News
Photonova Spectra is powered by GE HealthCare's proprietary Deep Silicon detector technology and combines ultra-high-definition imaging with spectral capabilities through a single-scan workflow. Its advanced imaging features are designed to improve spatial resolution and material characterization, creating opportunities for quantitative imaging, tissue assessment and research into new spectral biomarkers.
The expanded research network includes Keio University Hospital in Japan, Centro Cardiologico Monzino IRCCS in Italy, Universitätsspital Zürich in Switzerland, the University of Wisconsin–Madison and Stanford Medicine in the United States. Researchers at these institutions will examine applications spanning cardiovascular imaging, coronary CT angiography, radiation dose optimization, reconstruction methods, quantitative imaging protocols, tissue characterization and potential imaging biomarkers. Wisconsin and Stanford have expanded their existing collaborations with GE HealthCare to investigate the system's technical capabilities and potential clinical applications.
The network also builds on existing collaborations with UZ Brussel in Belgium and Rigshospitalet in Denmark. Their research focuses on advanced cardiac imaging, pediatric and low-dose imaging, tissue characterization and spectral applications in complex clinical cases.
Through these collaborations, GE HealthCare's engineers, scientists and product specialists will work alongside clinicians and researchers to evaluate the system's capabilities and identify opportunities for further development. Insights from these studies could help refine imaging protocols, improve clinical workflows and guide future enhancements to Photonova Spectra, while contributing to the broader advancement of photon-counting CT technology.
Industry Prospects Favoring the Market
According to Global Market Insights, the global photon-counting CT market is estimated to reach $395.1 million in 2026 and is projected to witness a CAGR of 24.7% through 2035.
Factors such as rising demand for high-resolution diagnostic imaging, increasing prevalence of cardiovascular diseases and cancer, growing adoption of advanced CT technologies, demand for improved tissue characterization, the need for lower radiation exposure and advancements in spectral imaging capabilities are driving market growth.
Other News
GE HealthCare recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Image: Shutterstock
GE HealthCare Expands Global Research Network for Photon-Counting CT
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced an expansion of its global clinical and research collaborations to advance Photonova Spectra, its next-generation photon-counting CT system. Seven leading healthcare and research institutions across North America, Europe and Asia will evaluate the technology across various clinical applications, imaging protocols and diagnostic settings. The initiative follows Photonova Spectra's CE Mark, FDA 510(k) clearance and regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency, supporting the next phase of its clinical adoption.
Per management, the company's Deep Silicon photon-counting CT technology has the potential to enhance clinicians' ability to visualize and interpret scans, opening new opportunities for early disease detection, personalized treatment and greater diagnostic confidence. GE HealthCare believes close collaboration with leading research institutions will help generate clinical evidence and real-world experience to establish new applications for the technology and support better patient care.
GEHC Stock Trend Following the News
Shares of GEHC have lost 1.4% since the announcement on Monday. Year to date, the stock has inched down 0.7% compared with the industry’s 15.3% fall. However, the S&P 500 has risen 7.2% during the same timeframe.
The expanded research network could strengthen GEHC's competitive position in the advanced medical imaging market and support the commercial potential of Photonova Spectra. Collaborations with prestigious healthcare institutions may help build clinical confidence in the technology, encourage broader adoption and create new demand across specialized imaging applications. The initiative also provides opportunities to refine the product based on real-world clinical feedback, reinforcing GE HealthCare's innovation leadership and supporting its long-term medical imaging growth.
GEHC currently has a market capitalization of $37.51 billion.
Image Source: Zacks Investment Research
More on the News
Photonova Spectra is powered by GE HealthCare's proprietary Deep Silicon detector technology and combines ultra-high-definition imaging with spectral capabilities through a single-scan workflow. Its advanced imaging features are designed to improve spatial resolution and material characterization, creating opportunities for quantitative imaging, tissue assessment and research into new spectral biomarkers.
The expanded research network includes Keio University Hospital in Japan, Centro Cardiologico Monzino IRCCS in Italy, Universitätsspital Zürich in Switzerland, the University of Wisconsin–Madison and Stanford Medicine in the United States. Researchers at these institutions will examine applications spanning cardiovascular imaging, coronary CT angiography, radiation dose optimization, reconstruction methods, quantitative imaging protocols, tissue characterization and potential imaging biomarkers. Wisconsin and Stanford have expanded their existing collaborations with GE HealthCare to investigate the system's technical capabilities and potential clinical applications.
The network also builds on existing collaborations with UZ Brussel in Belgium and Rigshospitalet in Denmark. Their research focuses on advanced cardiac imaging, pediatric and low-dose imaging, tissue characterization and spectral applications in complex clinical cases.
Through these collaborations, GE HealthCare's engineers, scientists and product specialists will work alongside clinicians and researchers to evaluate the system's capabilities and identify opportunities for further development. Insights from these studies could help refine imaging protocols, improve clinical workflows and guide future enhancements to Photonova Spectra, while contributing to the broader advancement of photon-counting CT technology.
Industry Prospects Favoring the Market
According to Global Market Insights, the global photon-counting CT market is estimated to reach $395.1 million in 2026 and is projected to witness a CAGR of 24.7% through 2035.
Factors such as rising demand for high-resolution diagnostic imaging, increasing prevalence of cardiovascular diseases and cancer, growing adoption of advanced CT technologies, demand for improved tissue characterization, the need for lower radiation exposure and advancements in spectral imaging capabilities are driving market growth.
Other News
GE HealthCare recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.